1
|
Alvarado Franco CA, Bernabeu García A, Suñol Sala J, Guerrero Villena J, Albero Amorós S, Llacer J, Delgado Navas RA, Ortiz JA, Pitas A, Castillo Farfan JC, Bernabeu Pérez R. Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial. Front Reprod Health 2023; 5:1239175. [PMID: 37965590 PMCID: PMC10642283 DOI: 10.3389/frph.2023.1239175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 10/13/2023] [Indexed: 11/16/2023] Open
Abstract
The present study compares two protocols for ovarian controlled stimulation in terms of number of cumulus-oocyte complexes and metaphase II oocytes. We employed a single injection of 150mcg of corifollitropin alfa after a 7-day oral contraceptive pill-free interval for TAIL group and a conventional administration of corifollitropin alfa after a 5-day OCP-free interval with additional rFSH from 8th of ovarian controlled stimulation. Prospective, randomized, comparative, non-inferiority, opened and controlled trial carried out in 180 oocyte donors 31 were excluded, 81 were randomized to the control group and 68 to the TAIL group. No differences were found in the number of follicles larger than 14 and 17 mm at triggering day. However, a lower number of cumulus-oocyte complexes and metaphase II oocytes were obtained in TAIL group compared to the control group, expressed as median (interquartile range): 10.5 (5.5-19) vs. 14 [11-21] and 9 (4-13) vs. 12 (9-17) respectively. Additionally, the incidence of failed retrieval or metaphase II oocytes = 0 was higher in TAIL group 7(10.3%) vs. 1(1.2%) p = 0.024. The use of a single injection of corifollitropin alfa after a 7-day oral contraceptive pill-free interval in oocyte donors resulted in a lower number of cumulus-oocyte complexes and metaphase II oocytes. No additional rFSH was administered in this group. Clinical Trial Registration: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001343-44/results.
Collapse
Affiliation(s)
| | | | - Jordi Suñol Sala
- Department of Gynecology, Instituto Bernabeu, Palma de Mallorca, Spain
| | | | | | - Joaquin Llacer
- Department of Gynecology, Instituto Bernabeu, Alicante, Spain
| | | | | | - Anna Pitas
- Clinical Trials Project Manager, Instituto Bernabeu, Alicante, Spain
| | - Juan Carlos Castillo Farfan
- Department of Gynecology, Instituto Bernabeu, Alicante, Spain
- Community Medicine and Reproductive Health Chair, Miguel Hernandez University, Elche, Spain
| | - Rafael Bernabeu Pérez
- Community Medicine and Reproductive Health Chair, Miguel Hernandez University, Elche, Spain
- Management Department, Instituto Bernabeu, Alicante, Spain
| |
Collapse
|